Microvionin
| Internal ID | 3637396b-2fd0-444a-8199-3a350dfcadff |
| Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > Peptides > Cyclic peptides |
| IUPAC Name | N-[1-[[(20Z)-14-(3-amino-3-oxopropyl)-17-(hydroxymethyl)-6-(2-methylpropyl)-2,5,8,12,15,18-hexaoxo-22-thia-1,4,7,13,16,19-hexazaspiro[10.12]tricos-20-en-9-yl]amino]-1-oxopropan-2-yl]-15-[(N,N'-dimethylcarbamimidoyl)amino]pentadecanamide |
| SMILES (Canonical) | CC(C)CC1C(=O)NCC(=O)NC2(CC(C(=O)N1)NC(=O)C(C)NC(=O)CCCCCCCCCCCCCCNC(=NC)NC)CSC=CNC(=O)C(NC(=O)C(NC2=O)CCC(=O)N)CO |
| SMILES (Isomeric) | CC(C)CC1C(=O)NCC(=O)NC2(CC(C(=O)N1)NC(=O)C(C)NC(=O)CCCCCCCCCCCCCCNC(=NC)NC)CS/C=C\NC(=O)C(NC(=O)C(NC2=O)CCC(=O)N)CO |
| InChI | InChI=1S/C45H78N12O10S/c1-29(2)24-32-39(63)51-26-37(61)57-45(28-68-23-22-49-40(64)34(27-58)55-41(65)31(56-43(45)67)19-20-35(46)59)25-33(42(66)53-32)54-38(62)30(3)52-36(60)18-16-14-12-10-8-6-7-9-11-13-15-17-21-50-44(47-4)48-5/h22-23,29-34,58H,6-21,24-28H2,1-5H3,(H2,46,59)(H,49,64)(H,51,63)(H,52,60)(H,53,66)(H,54,62)(H,55,65)(H,56,67)(H,57,61)(H2,47,48,50)/b23-22- |
| InChI Key | XATUQCHCLJEEGO-FCQUAONHSA-N |
| Popularity | 1 reference in papers |
| Molecular Formula | C45H78N12O10S |
| Molecular Weight | 979.20 g/mol |
| Exact Mass | 978.56845791 g/mol |
| Topological Polar Surface Area (TPSA) | 358.00 Ų |
| XlogP | 1.90 |
| Atomic LogP (AlogP) | -0.69 |
| H-Bond Acceptor | 12 |
| H-Bond Donor | 12 |
| Rotatable Bonds | 24 |
| N-[1-[[(20Z)-14-(3-amino-3-oxopropyl)-17-(hydroxymethyl)-6-(2-methylpropyl)-2,5,8,12,15,18-hexaoxo-22-thia-1,4,7,13,16,19-hexazaspiro[10.12]tricos-20-en-9-yl]amino]-1-oxopropan-2-yl]-15-[(N,N'-dimethylcarbamimidoyl)amino]pentadecanamide |
| 15-(N',n''-dimethylcarbamimidamido)-N-(1-(((14Z)-2,5,8,17,20,23-hexahydroxy-21-(2-(C-hydroxycarbonimidoyl)ethyl)-18-(hydroxymethyl)-6-(2-methylpropyl)-13-thia-1,4,7,16,19,22-hexaazaspiro(10.12)tricosa-1,4,7,14,16,19,22-heptaen-9-yl)-C-hydroxycarbonimidoyl)ethyl)pentadecanimidate |
| 15-(N',n''-dimethylcarbamimidamido)-N-(1-{[(14Z)-2,5,8,17,20,23-hexahydroxy-21-[2-(C-hydroxycarbonimidoyl)ethyl]-18-(hydroxymethyl)-6-(2-methylpropyl)-13-thia-1,4,7,16,19,22-hexaazaspiro[10.12]tricosa-1,4,7,14,16,19,22-heptaen-9-yl]-C-hydroxycarbonimidoyl}ethyl)pentadecanimidate |
| N-(1-(((20Z)-14-(3-amino-3-oxopropyl)-17-(hydroxymethyl)-6-(2-methylpropyl)-2,5,8,12,15,18-hexaoxo-22-thia-1,4,7,13,16,19-hexazaspiro(10.12)tricos-20-en-9-yl)amino)-1-oxopropan-2-yl)-15-((N,N'-dimethylcarbamimidoyl)amino)pentadecanamide |
| RefChem:158810 |
| SCHEMBL18360968 |
| SCHEMBL30956917 |
| CHEBI:219351 |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.7324 | 73.24% |
| Caco-2 | - | 0.8556 | 85.56% |
| Blood Brain Barrier | - | 0.7250 | 72.50% |
| Human oral bioavailability | - | 0.7429 | 74.29% |
| Subcellular localzation | Mitochondria | 0.5993 | 59.93% |
| OATP2B1 inhibitior | - | 0.8604 | 86.04% |
| OATP1B1 inhibitior | + | 0.8544 | 85.44% |
| OATP1B3 inhibitior | + | 0.9354 | 93.54% |
| MATE1 inhibitior | - | 0.8800 | 88.00% |
| OCT2 inhibitior | - | 0.7500 | 75.00% |
| BSEP inhibitior | + | 0.9529 | 95.29% |
| P-glycoprotein inhibitior | + | 0.7448 | 74.48% |
| P-glycoprotein substrate | + | 0.8827 | 88.27% |
| CYP3A4 substrate | + | 0.7215 | 72.15% |
| CYP2C9 substrate | - | 0.8060 | 80.60% |
| CYP2D6 substrate | - | 0.8452 | 84.52% |
| CYP3A4 inhibition | - | 0.8894 | 88.94% |
| CYP2C9 inhibition | - | 0.7930 | 79.30% |
| CYP2C19 inhibition | - | 0.7592 | 75.92% |
| CYP2D6 inhibition | - | 0.8932 | 89.32% |
| CYP1A2 inhibition | - | 0.8166 | 81.66% |
| CYP2C8 inhibition | + | 0.7336 | 73.36% |
| CYP inhibitory promiscuity | - | 0.9826 | 98.26% |
| UGT catelyzed | + | 0.9000 | 90.00% |
| Carcinogenicity (binary) | - | 0.8600 | 86.00% |
| Carcinogenicity (trinary) | Non-required | 0.5599 | 55.99% |
| Eye corrosion | - | 0.9794 | 97.94% |
| Eye irritation | - | 0.8992 | 89.92% |
| Skin irritation | - | 0.7506 | 75.06% |
| Skin corrosion | - | 0.9136 | 91.36% |
| Ames mutagenesis | - | 0.6800 | 68.00% |
| Human Ether-a-go-go-Related Gene inhibition | - | 0.3761 | 37.61% |
| Micronuclear | + | 0.7000 | 70.00% |
| Hepatotoxicity | - | 0.6073 | 60.73% |
| skin sensitisation | - | 0.8139 | 81.39% |
| Respiratory toxicity | + | 0.7778 | 77.78% |
| Reproductive toxicity | + | 0.8333 | 83.33% |
| Mitochondrial toxicity | + | 0.7875 | 78.75% |
| Nephrotoxicity | - | 0.6546 | 65.46% |
| Acute Oral Toxicity (c) | III | 0.5781 | 57.81% |
| Estrogen receptor binding | + | 0.7625 | 76.25% |
| Androgen receptor binding | + | 0.6919 | 69.19% |
| Thyroid receptor binding | - | 0.5000 | 50.00% |
| Glucocorticoid receptor binding | + | 0.5720 | 57.20% |
| Aromatase binding | + | 0.6763 | 67.63% |
| PPAR gamma | + | 0.7274 | 72.74% |
| Honey bee toxicity | - | 0.6398 | 63.98% |
| Biodegradation | - | 0.7750 | 77.50% |
| Crustacea aquatic toxicity | + | 0.5624 | 56.24% |
| Fish aquatic toxicity | - | 0.5000 | 50.00% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL230 | P35354 | Cyclooxygenase-2 | 99.53% | 89.63% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.25% | 96.09% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.20% | 91.11% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.07% | 98.95% |
| CHEMBL220 | P22303 | Acetylcholinesterase | 98.20% | 94.45% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 97.71% | 94.66% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 97.23% | 94.45% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 97.00% | 98.05% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 96.80% | 83.82% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 96.00% | 93.10% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 95.98% | 97.25% |
| CHEMBL2208 | P49137 | MAP kinase-activated protein kinase 2 | 95.58% | 95.20% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 94.02% | 90.71% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 94.00% | 94.75% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 93.60% | 91.03% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 93.60% | 96.90% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 92.56% | 97.29% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 92.40% | 96.11% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 91.70% | 96.33% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 91.57% | 90.08% |
| CHEMBL4026 | P40763 | Signal transducer and activator of transcription 3 | 91.57% | 82.69% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 91.06% | 90.17% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 91.06% | 95.50% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 91.03% | 95.00% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 90.54% | 99.17% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 90.50% | 100.00% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 90.15% | 97.23% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 90.01% | 97.09% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 88.83% | 99.23% |
| CHEMBL5261 | Q7L7X3 | Serine/threonine-protein kinase TAO1 | 88.75% | 89.33% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 88.62% | 95.71% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 88.05% | 92.32% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 87.24% | 92.88% |
| CHEMBL1255126 | O15151 | Protein Mdm4 | 86.36% | 90.20% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 85.80% | 96.61% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 85.36% | 94.33% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 85.07% | 98.59% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 84.92% | 96.47% |
| CHEMBL4481 | P35228 | Nitric oxide synthase, inducible | 84.81% | 94.80% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 84.59% | 88.42% |
| CHEMBL4101 | P17612 | cAMP-dependent protein kinase alpha-catalytic subunit | 84.18% | 82.86% |
| CHEMBL259 | P32245 | Melanocortin receptor 4 | 83.21% | 95.38% |
| CHEMBL3880 | P07900 | Heat shock protein HSP 90-alpha | 82.74% | 96.21% |
| CHEMBL4374 | Q9Y5X4 | Photoreceptor-specific nuclear receptor | 82.69% | 85.00% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 82.41% | 98.33% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 82.26% | 89.34% |
| CHEMBL1980 | Q14524 | Sodium channel protein type V alpha subunit | 82.26% | 92.50% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 82.19% | 100.00% |
| CHEMBL344 | Q99705 | Melanin-concentrating hormone receptor 1 | 80.95% | 92.50% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 80.88% | 100.00% |
| CHEMBL5646 | Q6L5J4 | FML2_HUMAN | 80.74% | 100.00% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 80.51% | 95.83% |
| CHEMBL1744525 | P43490 | Nicotinamide phosphoribosyltransferase | 80.10% | 96.25% |
| CHEMBL2443 | P49862 | Kallikrein 7 | 80.02% | 94.00% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 124173895 |
| LOTUS | LTS0169208 |
| wikiData | Q105324147 |